Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients
Top Cited Papers
- 6 April 2017
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 376 (14), 1321-1331
- https://doi.org/10.1056/nejmoa1700456
Abstract
Although transcatheter aortic-valve replacement (TAVR) is an accepted alternative to surgery in patients with severe aortic stenosis who are at high surgical risk, less is known about comparative outcomes among patients with aortic stenosis who are at intermediate surgical risk. We evaluated the clinical outcomes in intermediate-risk patients with severe, symptomatic aortic stenosis in a randomized trial comparing TAVR (performed with the use of a self-expanding prosthesis) with surgical aortic-valve replacement. The primary end point was a composite of death from any cause or disabling stroke at 24 months in patients undergoing attempted aortic-valve replacement. We used Bayesian analytical methods (with a margin of 0.07) to evaluate the noninferiority of TAVR as compared with surgical valve replacement. A total of 1746 patients underwent randomization at 87 centers. Of these patients, 1660 underwent an attempted TAVR or surgical procedure. The mean (±SD) age of the patients was 79.8±6.2 years, and all were at intermediate risk for surgery (Society of Thoracic Surgeons Predicted Risk of Mortality, 4.5±1.6%). At 24 months, the estimated incidence of the primary end point was 12.6% in the TAVR group and 14.0% in the surgery group (95% credible interval [Bayesian analysis] for difference, −5.2 to 2.3%; posterior probability of noninferiority, >0.999). Surgery was associated with higher rates of acute kidney injury, atrial fibrillation, and transfusion requirements, whereas TAVR had higher rates of residual aortic regurgitation and need for pacemaker implantation. TAVR resulted in lower mean gradients and larger aortic-valve areas than surgery. Structural valve deterioration at 24 months did not occur in either group. TAVR was a noninferior alternative to surgery in patients with severe aortic stenosis at intermediate surgical risk, with a different pattern of adverse events associated with each procedure. (Funded by Medtronic; SURTAVI ClinicalTrials.gov number, NCT01586910.)Keywords
This publication has 19 references indexed in Scilit:
- Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk PatientsThe New England Journal of Medicine, 2016
- 3-Year Outcomes in High-Risk Patients Who Underwent Surgical or Transcatheter Aortic Valve ReplacementJournal of the American College of Cardiology, 2016
- Annual Outcomes With Transcatheter Valve TherapyThe Annals of Thoracic Surgery, 2015
- 1-Year Outcomes After Transfemoral Transcatheter or Surgical Aortic Valve ReplacementJournal of the American College of Cardiology, 2015
- 2-Year Outcomes in Patients Undergoing Surgical or Self-Expanding Transcatheter Aortic Valve ReplacementJournal of the American College of Cardiology, 2015
- Transcatheter Aortic-Valve Replacement with a Self-Expanding ProsthesisThe New England Journal of Medicine, 2014
- Transcatheter Aortic Valve Replacement Using a Self-Expanding Bioprosthesis in Patients With Severe Aortic Stenosis at Extreme Risk for SurgeryJournal of the American College of Cardiology, 2014
- Outcomes of surgical aortic valve replacement in moderate risk patients: Implications for determination of equipoise in the transcatheter eraThe Journal of Thoracic and Cardiovascular Surgery, 2014
- A 3-Center Comparison of 1-Year Mortality Outcomes Between Transcatheter Aortic Valve Implantation and Surgical Aortic Valve Replacement on the Basis of Propensity Score Matching Among Intermediate-Risk Surgical PatientsJACC: Cardiovascular Interventions, 2013
- Updated standardized endpoint definitions for transcatheter aortic valve implantation: The Valve Academic Research Consortium-2 consensus documentThe Journal of Thoracic and Cardiovascular Surgery, 2013